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Abstract
Background: Pathological changes in periodontal tissues are mediated by the interaction between microorganisms
and the host immune-inflammatory response. Hyperglycemia may interfere with this process. The aim of this study
was to compare the levels of 27 inflammatory molecules in the gingival crevicular fluid (GCF) of patients with type
2 diabetes, with and without chronic periodontitis, and of chronic periodontitis subjects without diabetes. A
putative correlation between glycated haemoglobin (HbA1c) and levels of the inflammatory molecules was also
investigated.
Methods: The study population comprised a total of 108 individuals, stratified into: 54 with type 2 diabetes and
chronic periodontitis (DM + CP), 30 with chronic periodontitis (CP) and 24 with type 2 diabetes (DM). Participants
were interviewed with the aid of structured questionnaire. Periodontal parameters (dental plaque, bleeding on
probing and periodontal pocket depth) were recorded. The GCF levels of the 27 inflammatory molecules were
measured using multiplex micro-bead immunoassay. A glycated haemoglobin (HbA1c) test was performed for
patients with diabetes by boronate affinity chromatography.
Results: After adjustment for potential confounders, the DM + CP group had higher levels of IL-8 and MIP-1β, and
lower levels of TNF-α, IL-4, INF-γ, RANTES and IL-7 compared to the CP group. Moreover, the DM + CP group had
lower levels of IL-6, IL-7 and G-CSF compared to the DM group. The DM group had higher levels of IL-10, VEGF,
and G-CSF compared to the CP group. The levels of MIP-1α and FGF were lower in diabetes patients (regardless of
their periodontal status) than in chronic periodontitis subjects without diabetes. Diabetes patients (DM + CP and
DM) had higher Th-2/Th-1 ratio compared to the CP group. HbA1c correlated positively with the pro-inflammatory
cytokines (Pearson correlation coefficient = 0.27, P value: 0.02).
Conclusion: Type 2 diabetes and chronic periodontitis may influence the GCF levels of inflammatory molecules
synergistically as well as independently. Type 2 diabetes was associated with high Th-2/Th-1 ratio, and modulated
the local expression of molecules involved in the anti-inflammatory and healing processes.
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Background
Diabetes mellitus represents a heterogeneous group of
metabolic disorders in which elevated blood glucose
levels result in disturbance of carbohydrate, fat and pro-
tein metabolism [1]. The most common form is type 2
diabetes [2]. Diabetes is a major public health concern
with 380 million people suffering from the disease
worldwide, and about 80 % of the patients are from low-
and middle-income countries [3]. It is expected that
Africa will take the lead in terms of the largest pro-
portional increase in adults with diabetes by 2030 [4].
Prevalence of diabetes in The Sudan, as in many
other low-income countries, is increasing to epidemic
proportions [5]. In 2014, the prevalence of the disease
in The Sudan was about 18 % [3], which ranks The
Sudan among countries with high prevalence of dia-
betes in Africa and the world. It also reflects the change in
life style and the urbanization movement of the population.
Chronic hyperglycemia is associated with irreversible
complications such as nephropathy, retinopathy, neur-
opathy, cardiovascular diseases, peripheral vascular dis-
eases, delayed healing and periodontal diseases [6].
Periodontal diseases, including the reversible form (gin-
givitis), are highly prevalent and affect up to 90 % of
adults worldwide [7]. Chronic periodontitis is character-
ized by apical migration of the epithelial attachment ac-
companied by loss of connective tissue and alveolar
bone [8]. These changes are mediated by the interaction
between pathogens and the host immune-inflammatory
response [9]. Although periodontal pathogens are con-
sidered as the initiative factor of the disease, [10] tissue
destruction in chronic periodontitis is the consequence
of the host response to those pathogens [11].
The exact mechanism by which diabetes affects peri-
odontal tissues is not fully elucidated [12]. An altered
immune-inflammatory response to bacterial pathogens
has been suggested [11]. Hyperglycemia can affect peri-
odontal tissues by increasing oxidative stress as a result
of the imbalance between reactive oxygen species and
antioxidants, which may eventually lead to accumulation
of Advanced Glycation End products (AGE) [13]. The
binding of AGE to their receptors (RAGE) triggers intra-
cellular events that enhance the production of pro-
inflammatory cytokines, chemokines and cell adhesion
molecules [14]. Hyperglycemia can be assessed by measur-
ing the concentration of glycated haemoglobin (HbA1c),
which reflects mean glucose levels over the previous 8–12
weeks [15].
One means of investigating the local inflammatory sta-
tus of the oral cavity is by analysis of gingival crevicular
fluid (GCF), a non-invasive approach for assessing the
presence or absence of various inflammatory molecules
[16]. GCF is a transudate or an inflammatory exudate that
can be collected from the gingival crevice surrounding the
teeth. It contains components of circulating blood, local
tissues and most importantly, host-derived inflammatory
molecules [16, 17].
Most of the studies of GCF inflammatory molecules in
individuals with diabetes have generally been based on
small subject samples and investigation of a limited
number of inflammatory molecules, with inconclusive
results [12]. Multiplex analysis of inflammatory mole-
cules, whereby a large number of inflammatory mole-
cules can be investigated at the same time, would
facilitate understanding of the inflammatory process in-
volved in both diabetes and periodontal diseases.
The aim of this study was to investigate the effect of
type 2 diabetes on the local expression of inflammatory
molecules involved in periodontal inflammation and
healing by comparing GCF levels of 27 inflammatory
molecules in patients with type 2 diabetes, with and
without chronic periodontitis, and in chronic periodon-
titis subjects without diabetes. A putative correlation be-
tween HbA1c and the molecules under investigation was
also explored. We tested the hypothesis that type 2 dia-
betes adversely influences the local expression of the in-
flammatory molecules under investigation.
Methods
Study design and participants
In all, 108 individuals were enrolled in the study, repre-
senting a randomly selected subset from 461 participants
recruited for a previous study by Mohamed et al. [18].
The subjects were stratified into three groups: 54 with
type 2 diabetes and chronic periodontitis (DM + CP), 30
with chronic periodontitis (CP) and 24 with type 2 dia-
betes (DM). The study participants were aged 24-70
years. Diabetes patients were recruited from The Jaber
Abol’ez Diabetes Center in Khartoum-Sudan. Diabetes
was diagnosed by specialist physicians at the center ac-
cording to the criteria of The American Diabetes Associ-
ation [19]. Whole blood samples obtained from patients
with diabetes were analysed for HbA1c by boronate af-
finity chromatography using a commercially available kit
(LabonaCheck™ A1c analyzer) [20]. The CP group was
recruited from the out-patient dental clinic at the
Khartoum Dental Teaching Hospital. Recruitment of
study participants and eligibility criteria for enrolment
have been described earlier [18]. Briefly, criteria for en-
rolment were (i), being diagnosed with type 2 diabetes
for more than one year and attending a specialized dia-
betes clinic -for patients with diabetes- (ii), having at
least 10 remaining teeth (iii), no antibiotic, no steroidal
and/or non-steroidal anti-inflammatory medication used
during the last 3 weeks (iv), not treated with immuno-
suppressive chemotherapy, no current acute illness, no
professional periodontal treatment received during the
last 6 months and no ongoing pregnancy or lactation.
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Demographic data were obtained from the study partici-
pants by means of a structured questionnaire.
The study protocol was approved by The Ministry of
Health in The Sudan and The Norwegian Research Ethics
Committee at The University of Bergen (2012/1470/REK
Vest). The study participants were enrolled between July
and December 2012. Written informed consent was
obtained from each participant after the project ob-
jectives, the steps in the oral clinical examination
and the sampling procedures had been explained.
The participants were informed of their dental diag-
nosis and referred for appropriate dental treatment if
indicated.
Clinical periodontal examination
All clinical assessments, group allocations and sampling-
site selection were undertaken by a single, calibrated
examiner (HGM). The periodontal examination included
all teeth except the 3rd molars using a color-coded peri-
odontal probe (N22, 2-4-6-8-10-12 mm markings), a
color-coded Nabors furcation probe (NAB2, 3-6-9-12
mm markings), curette, mirror, probe, tweezers and cot-
ton rolls. The clinical examination comprised dental
plaque assessment using the Silness and Loe Index [21],
bleeding on probing (BoP), scored as present or absent,
and probing depth (measured from the gingival margin
to the base of the periodontal pocket in millimeters) at
four sites on each tooth (mesial, distal, buccal and lin-
gual). Participants were diagnosed as having chronic
periodontitis if they had at least two sites with bleeding
pockets of ≥ 4 mm (not on the same tooth) [22, 23]. The
oral examination was repeated for 20 participants ran-
domly selected within 2 weeks. Intra-examiner reliability
was assessed by Cohen's kappa coefficient [24]. Kappa
value (κ) was 0.88 for chronic periodontitis (yes/no).
GCF sampling
GCF samples were collected using perio-paper strips,
(PERIOPAPER® Gingival Fluid Collection Strips, Oraflow
Inc., New York, USA). Four samples, each representing
a quadrant, were collected from each participant. The
strip was inserted into the mesiobuccal site of the sul-
cus/pocket of the 1st molar. If missing, the 2nd molar,
2nd premolar or 1st premolar was sampled, respectively.
Quadrants with no posterior teeth were excluded from
the sampling. After the supra-gingival biofilm had been
removed with sterile cotton pellets, the sites were dried
and isolated with cotton rolls. The paper strips were
inserted 2 mm into the sulcus/pocket and left in place
for 30 s. Strips that were visually assessed as contami-
nated with blood or saliva were discarded. The 4 strips
were immediately pooled in one tube, labeled and stored
in liquid nitrogen for further analysis.
Protein extraction and quantification
For protein extraction, Tween buffer (230 μl) was added
to each of the tubes containing the 4 strips. The tubes
were shaken for 30 min and then centrifuged for 10 min
at 4 °C and 1400 rpm. The extracted protein was quanti-
fied using a commercially available kit and following the
manufacturer's instructions (Pierce™ BCA Protein Assay
Kit, Thermo scientific, Rockford, USA). Absorbance was
measured at 560 nm on a plate reader (FLUOstar
OPTIMA- BMG Labtech, Germany). Total protein
per sample (4 strips) was calculated in micrograms (μg).
Analysis and grouping of inflammatory molecules
Following protein extraction, GCF samples (20 μl each)
were processed by multiplex immunoassay containing
fluorescent dyed microspheres conjugated with mono-
clonal antibody specific for 27 inflammatory molecules
(Bio-Plex Human Cytokine Assay; Bio-Rad Inc., Hercules,
CA, USA) [25]. The following molecules were investi-
gated: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, Basic
Fibroblast Growth Factor (FGF), Granulocyte Colony
Stimulating Factor (G-CSF), Granulocyte-Monocyte Col-
ony Stimulating Factor (GM-CSF), Interferon-γ (INF-γ),
Interferon Inducible Protein-10 (IP-10), Monocyte
Chemo-attractive Protein-1 (MCP-1), Macrophage In-
flammatory Protein-1α (MIP-1α), Macrophage Inflam-
matory Protein-1β (MIP-1β), Platelet-Derived Growth
Factor (PDGF), Regulated Upon Activation, Normally
T-Expressed, and Presumably Secreted (RANTES),
Tumor Necrosis Factor-α (TNF-α) and Vascular Endo-
thelial Growth Factor (VEGF). Samples were diluted
1:4 (50 μl in total) and incubated with coupled beads.
Complexes were washed, incubated with detection anti-
body and thereafter, with Streptavidin-Phycoerythrin. A
range of 105876 – 0.29 pg/ml recombinant cytokines was
used to establish the standard curves. The levels of the
inflammatory molecules were measured on a multi-
plex array reader (Bio-Plex Workstation from Bio-Rad
Laboratories). The final quantities were calculated
using software provided by the manufacturer and
were reported as picograms per 30 s (pg/30 s) [26].
Based on the biological effect of each molecule, the
molecules under investigation were grouped as: pro-
inflammatory cytokines (IL-1β, IL-6, IL-9, IL-12 and
TNF-α), anti-inflammatory cytokines (IL-4 and IL-10),
chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β and
RANTES) and T-helper 2/T-helper 1 ratio (Th-2/Th-1)
(IL-4, IL-6, IL-9, IL-10/INF-γ, IL-2).
Statistical analysis
Inter-group differences in demographic and clinical
data were assessed using chi-square and Fisher’s
exact test for categorical variables, one way analysis
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of variance (ANOVA) with post-hoc (Sidak) adjust-
ment for multiple comparisons for normally distrib-
uted continuous variables, and Kruskal-Wallis and
Mann-Whitney test for skewed data. Since the distri-
bution of the levels of the studied molecules is
skewed, the natural logarithm links were calculated
and used to detect the differences between the study
groups, and one way analysis of variance (ANOVA)
with post-hoc (Sidak) was conducted. Generalized
linear models (GLM) with Gaussian family and log
function were used to adjust for the potentially con-
founding effect of age, gender, smoking status, dental
plaque, BoP and total protein on the outcome (mol-
ecule quantities). A possible correlation between
HbA1c and the inflammatory status was investigated
using Pearson correlation. Stata 13 (StataCorp. 2013.
Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP.) was used for data analysis. P
values less than 0.05 were considered statistically
significant.
Results
The demographic characteristics and clinical parame-
ters of the study groups are presented in Table 1.
BoP was the only clinical parameter that differed sig-
nificantly between the groups. It was higher in the
DM + CP group than in the CP and DM groups. The
following inflammatory molecules, which were not
detected in more than 30 % of the GCF samples,
were excluded from the analysis: (IL-1ra, IL-5, IL-13,
IL-15 and eotaxin). The unadjusted means of the
quantities of the detected molecules across the study
groups are presented in Table 2. After adjustment
for potential confounders (age, gender, smoking sta-
tus, BoP, dental plaque index and total protein), the
DM + CP group had higher levels of IL-8 and MIP-
1β, and lower levels of TNF-α, IL-4, INF-γ, RANTES
and IL-7 compared to the CP group. Moreover, the
DM + CP group had lower levels of IL-6, IL-7 and
G-CSF than the DM group. The DM group had
higher levels of IL-10, VEGF, and G-CSF than the
CP group. Both diabetes groups (DM+CP and DM) had
lower levels of MIP-1α and FGF compared to chronic
periodontitis subjects without diabetes (CP) (Table 3).
The Th-2/Th-1 ratio was significantly higher in the
diabetes groups (DM +CP and DM) than in the CP
group (Fig. 1d). A weak positive correlation was ob-
served between HbA1c and the levels of the pro-
inflammatory cytokines (Pearson correlation coefficient:
0.27, P value: 0.02) (Fig. 2), while the correlation be-
tween HbA1c and the anti-inflammatory cytokines was
not statistically significant (Pearson correlation coeffi-
cient: -0.11, P value: 0.33) (Fig. 3).
Discussion
Pro-inflammatory cytokines induce inflammatory re-
sponse to various stimuli such as bacterial lipopolysac-
charides [27]. In patients with diabetes, IL-1β is
regarded as one of the key cytokines in inflammatory
periodontal tissue destruction [28]. In the present study,
the level of IL-1β was highest in the DM+CP group,
Table 1 Distribution of socio-demographic and clinical indicators
by study groups
Variable DM + CP (n = 54) CP (n = 30) DM (n = 24)
Age, mean (SE)1 54.76 (1.37) 55.37 (1.83) 50.79 (2.05)
Gender, % (n)2
Male 42.59 (23) 60.00 (18) 29.17 (7)
Female 57.41 (31) 40.00 (12) 70.83 (17)
Education, % (n)2
Illiterate 29.63 (16) 33.33 (10) 20.83 (5)
Literate 70.37 (38) 66.67 (20) 79.17 (19)
Employment, % (n)2
Unemployed 62.96 (34) 43.33 (13) 70.83 (17)
Employed 37.04 (20) 56.67 (17) 29.17 (7)
Smoking, % (n)3
Yes 12.96 (7) 26.67 (8) 12.50 (3)
No 87.04 (47) 73.33 (22) 87.50 (21)
Hypertension, % (n)2
Yes 31.48 (17) 20.00 (6) 29.17 (7)
No 68.52 (37) 80.00 (24) 70.83 (17)
Regular dental
attendance, % (n)3
Yes 3.70 (2) 10.00 (3) 8.33 (2)
No 96.30 (52) 90.00 (27) 91.67 (22)
Duration of diabetes,
mean (SE)4
8.44 (0.83) ——— 9.67 (1.70)
HbA1c %, mean (SE)5 9.17 (0.24) ——— 9.25 (0.49)
Plaque index, mean
(SE)1
1.66 (0.05) 1.40 (0.06) 1.47 (0.07)
Percentage of teeth
with BoP, mean (SE)1
58.88 (2.85)a 28.97 (3.82)b** 32.51 (4.28)b**
Pocket depth, % (n)2
4-5 mm 59.30 (32) 70.00 (21) 0.00 (0)
≥6 mm 40.70 (22) 30.00 (9) 0.00 (0)
Pocket depth, mean
(SE)4
4.16 (0.09) 4.25 (0.12) ———
Total protein -μg,
mean (SE)6
82.78 (7.53) 84.23 (15.25) 77.84 (9.06)
Different letters indicate statistically significant differences
1one-way ANOVA
2chi-square test
3Fisher’s exact test
4Mann-Whitney U test
5Independent sample T test
6Kruskal-Wallis test
**P < 0.01
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albeit not statistically significant. A recent meta-analysis
reported that type 2 diabetes patients with chronic peri-
odontitis were found to have significantly higher GCF
levels of IL-1β than their systemically healthy counter-
parts [29]. In contrast, others have failed to confirm an
association between levels of IL-1β and diabetes in indi-
viduals with periodontal disease [30, 31]. These incon-
sistencies might be attributed to the difference in HbA1c
levels and the duration of diabetes. Contradictory results
were reported from studies of TNF-α levels in oral fluids
among patients with diabetes and chronic periodontitis
[12]. In the present study, the levels of both TNF-α and
IL-7 were lower in the DM+ CP group than in the CP
group. In contrast, other studies have reported higher
GCF levels of TNF-α and IL-7 in patients with type 2
diabetes than in systemically healthy individuals [29, 32].
In this context, it is of interest to note that the levels of
pro-inflammatory cytokines and chemokines in the DM
group were comparable with those in the CP group,
reflecting a local active inflammatory process in the DM
group (Fig. 1a–1c). A weak positive correlation was ob-
served between HbA1c and the levels of pro-
inflammatory cytokines. Another study reported a sig-
nificant positive correlation between IL-1β levels in GCF
and HbA1c [33].
Studying the effect of IL-6 and IL-10, particularly in
cross-sectional studies, is complicated by the fact that
both are multifunctional cytokines (i.e. pro- and anti-
inflammatory) [34, 35]. IL-6 is involved in activation of
osteoclasts and Th-17 cells [36]. In contrast, it also in-
duces the production of IL-1ra, thus contributes to the
anti-inflammatory process [37]. There is no evidence to
support an association between increased levels of IL-6
and destructive periodontal disease among individuals
with hyperglycemia [38]. However, Javed et al., [39] re-
ported that up-regulation of IL-6 together with IL-1α
could be associated with diabetes related periodontal tis-
sue destruction. In the present study, the levels of the
anti-inflammatory cytokine IL-4 were lower in the
DM + CP group than in the CP group. It has been re-
ported that IL-4 is down-regulated in patients with type 2
diabetes [40]. In addition, in an in-vivo animal model for
ligament healing, IL-4 was found to contribute to the
proliferative phase of healing [41].
Chemokines are small peptides that recruit immune
cells from the circulation to the tissues as needed [42].
Most investigations of the role of chemokines have fo-
cused on IL-8 [12]. In the present study, IL-8 was up-
regulated in the DM+CP group compared to the CP
Table 2 Levels of the detected inflammatory molecules among
the study groups (pg/30s)
Inflammatory
molecule, mean (SE)
DM + CP (n = 54) CP (n = 30) DM (n = 24)
IL-1β 350.50 (31.18) 260.31 (41.45) 261.74 (46.34)
IL-6 9.01 (0.83)a 11.12 (1.11)ab 12.67 (1.27)b*
IL-9 6.91 (0.57) 9.64 (0.76) 8.57 (0.87)
IL-12 13.93 (1.07) 16.44 (1.43) 17.13 (1.63)
TNF-α 17.70 (1.84)a 31.57 (2.47)b** 22.05 (2.82)ab
IL-4 0.83 (0.06)a 1.26 (0.09)b** 0.92 (0.10)ab
IL-10 27.74 (1.43)ab 23.68 (1.90)a 33.02 (2.17)b**
IL-2 8.01 (0.98)a* 8.93 (1.30)a* 12.68 (1.48)b
INF-γ 29.55 (2.61)a** 47.50 (3.50)b 33.89 (3.92)a*
IL-8 633.87 (48.22) 501.96 (62.25) 507.65 (69.60)
IP-10 19.32 (2.30)a 24.60 (3.01)ab 29.13 (3.43)b*
MCP-1 6.10 (0.87)a 10.73 (1.11)b** 7.88 (1.24)ab
MIP-1α 3.14 (0.27)a* 4.52 (0.36)b 2.98 (0.40)a*
MIP-1β 23.53 (2.64) 21.37 (3.54) 26.03 (3.95)
RANTES 32.93 (2.77) 45.64 (3.72) 40.12 (4.16)
FGF 76.91 (4.62)a** 105.16 (6.20)b 76.34 (6.93)a*
PDGF 13.05 (0.93)a 17.22 (1.24)b* 15.45 (1.39)ab
VEGF 212.01 (11.75) 188.50 (15.77) 222.83 (17.63)
IL-7 2.63 (0.31)a 4.85 (0.42)b** 4.24 (0.47)b**
G-CSF 122.73 (12.48)a 131.02 (16.75)ab 196.73 (19.13)b**
GM-CSF 621.28 (21.82) 558.27 (29.28) 555.30 (33.44)
IL-17 72.04 (3.71)a 246.03 (62.90)b** 79.98 (6.68)ab
Different letters indicate statistically significant differences using one-way
ANOVA for natural log. links of the amounts of inflammatory molecules
*P < 0.05
**P < 0.01
Table 3 Adjusted means of the levels of inflammatory molecules
(pg/30s)
Inflammatory
molecule,
mean (SE)
DM + CP (n = 54) CP (n = 30) DM (n = 24)
IL-6 9.01 (0.94)a 11.11 (1.30)ab 14.01 (1.50)b*
TNF-α 17.68 (2.06)a 31.64 (3.16)b** 23.13 (3.20)ab
IL-4 0.84 (0.07)a 1.25 (0.11)b* 0.96 (0.11)ab
IL-10 28.82 (1.66)ab 22.46 (1.99)a 33.72 (2.42)b**
INF-γ 30.62 (2.99)a 45.77 (4.29)b* 36.88 (4.62)ab
IL-8 699.48 (53.44)a 464.17 (57.03)b* 503.04 (71.04)ab
MIP-1α 3.05 (0.32)a* 4.79 (0.47)b 2.99 (0.45)a*
MIP-1β 28.71 (3.05)a 16.84 (2.86)b* 22.37 (3.40)ab
RANTES 31.94 (3.14)a 48.01 (4.70)b* 41.16 (4.79)ab
FGF 71.66 (5.17)a** 113.28 (7.90)b 80.86 (7.93)a**
VEGF 215.04 (12.69)ab 177.52 (16.40)a 255.82 (19.39)b**
IL-7 2.81 (0.35)a 4.47 (0.51)b* 4.78 (0.56)b*
G-CSF 131.71 (14.41)a* 116.98 (17.79)a** 206.60 (21.25)b
Different letters indicate statistically significant differences using GLM with
Gaussian family and log. function adjusting for age, gender, smoking status,
BoP, dental plaque index and total protein
*P < 0.05
**P < 0.01
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Fig. 1 Levels of inflammatory molecules in GCF of the study groups. a: pro-inflammatory cytokines (IL-1β, IL-6, IL-9, IL-12, TNF-α), b: anti-inflammatory
cytokines (IL-4, IL-10), c: chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES), d: Th-2/Th-1 ratio: (IL-4, IL-6, IL-9, IL-10) / (INF-γ, IL-2), **: P < 0.01
Fig. 2 Correlation between HbA1c and the pro-inflammatory cytokines. Pearson correlation coefficient: 0.27, P value: 0.02
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group. The same trend has been observed in an investi-
gation of serum levels of IL-8 [43]. MIP-1α is a potent
chemokine that attracts macrophages, T-cytotoxic and
natural killer cells [44]. It was down-regulated in both
diabetes groups (DM+ CP and DM) compared to the
CP group. In contrast, Duarte et al., [32] reported higher
levels of MIP-1α in patients with poorly controlled type
2 diabetes compared to systemically healthy controls.
The present study demonstrated lower levels of
RANTES in the DM +CP group compared to the CP
group. It was reported that levels of RANTES negatively
correlate with increased inflammation [45].
Type 2 diabetes might adversely affect periodontal
health by down-regulating molecules involved in peri-
odontal tissue regeneration and healing process such as
FGF and PDGF [46, 47]. FGF was detected in lower
amounts in the diabetes groups (DM+ CP and DM)
than in the CP group. Moreover, the levels of VEGF
were higher in the DM group compared to the CP
group. This observation might be explained by the fact
that oxidative stress induces the VEGF signaling in pa-
tients with type 2 diabetes [48]. Moreover, our VEGF re-
sults corroborate with a previous study which reported a
non-significant trend towards increased VEGF in GCF
of patients with type 2 diabetes and chronic periodontitis
compared to systemically healthy individuals with
chronic periodontitis [49]. In contrast, Guneri et al., [50]
concluded that GCF levels of VEGF were elevated in
subjects with chronic periodontitis regardless of their
diabetic status.
According to the cytokines they produce, Th-cells are
divided into Th-1, Th-2, Th-17 and T-regulatory cells.
Th-1 secretes IL-2 and INF-γ, while Th-2 secretes IL-4,
IL-6, IL-9, IL-10 and IL-13 [51, 52]. Only limited infor-
mation is available about the role of Th-cells in type 2
diabetes patients with periodontitis [12]. Th-2/Th-1 ratio
was higher in both diabetes groups (DM +CP and DM)
than in the CP group, indicating enhanced humoral
response and progression of periodontal disease among
patients with type 2 diabetes via Th-2/B-cell axis [53, 54].
In the present study, the low levels of some of the pro-
inflammatory molecules detected in type 2 diabetes pa-
tients compared to those without diabetes can be ex-
plained by the fact that some of the patients with diabetes
were receiving insulin therapy, which might affect the
local expression of inflammatory molecules [43, 55].
Moreover, the more pronounced clinical signs of peri-
odontal disease in individuals with type 2 diabetes can be
attributed to the disturbance in the balance between the
molecules involved in active inflammatory process on
the one hand, and the molecules involved in control-
ling inflammation, healing and regeneration of periodontal
tissues on the other hand [56, 57]. Up to date, there is no
ideal biomarker that can be nominated for disease detection
or progression. Therefore, the interest has been shifted to-
wards considering combinations of various host responses
[11, 58]. In the present study, the GCF volume was not
measured. Therefore, total GCF protein was used as a sur-
rogate measure of the GCF volume in the multivariate ana-
lysis to control for the potential effect of variability of GCF
volume on our results [59]. In addition, pocket depth and
bleeding on probing were both used to define cases with
periodontitis, as clinical attachment loss data were not
available. Consequently, the effect of type 2 diabetes on the
study outcome might be underestimated [60]. Nevertheless,
it was reported that both periodontal pocket depth and
Fig. 3 Correlation between HbA1c and the anti-inflammatory cytokines. Pearson correlation coefficient: -0.11, P value: 0.33
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BoP reflect the current disease status and are strongly re-
lated to the local inflammatory activity compared to clinical
attachment loss, which reflects past disease experience
[61–63].
Conclusions
Type 2 diabetes and chronic periodontitis may adversely in-
fluence the GCF levels of inflammatory molecules synergis-
tically as well as independently. Moreover, type 2 diabetes
was associated with high Th-2/Th-1 ratio, and adversely in-
fluenced the local expression of molecules involved in the
anti-inflammatory and healing processes. Further prospect-
ive studies are warranted to produce sufficient evidence to
support the application of specific GCF biomarkers for pre-
diction and prognosis of periodontal disease among pa-
tients with diabetes.
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